These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 15971270

  • 1. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
    Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F.
    Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).
    Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M.
    J Immunol; 1995 Nov 01; 155(9):4376-81. PubMed ID: 7594597
    [Abstract] [Full Text] [Related]

  • 5. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.
    Leuk Res; 2006 May 01; 30(5):625-31. PubMed ID: 16289746
    [Abstract] [Full Text] [Related]

  • 6. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 May 01; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 7. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A.
    Invest Ophthalmol Vis Sci; 1996 Aug 01; 37(9):1884-91. PubMed ID: 8759358
    [Abstract] [Full Text] [Related]

  • 8. Immunization against tumor cell surface complement-regulatory proteins.
    Durrant LG, Spendlove I.
    Curr Opin Investig Drugs; 2001 Jul 01; 2(7):959-66. PubMed ID: 11757799
    [Abstract] [Full Text] [Related]

  • 9. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M.
    Lab Invest; 1996 Jan 01; 74(1):33-42. PubMed ID: 8569195
    [Abstract] [Full Text] [Related]

  • 10. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B, Ma ZW, Li H, Xu GL, Zheng P, Zhu B, Wu YZ, Zou Q.
    Clin Immunol; 2008 Aug 01; 128(2):155-63. PubMed ID: 18502181
    [Abstract] [Full Text] [Related]

  • 11. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
    Shimo K, Mizuno M, Nasu J, Hiraoka S, Makidono C, Okazaki H, Yamamoto K, Okada H, Fujita T, Shiratori Y.
    J Gastroenterol Hepatol; 2004 Jun 01; 19(6):643-7. PubMed ID: 15151618
    [Abstract] [Full Text] [Related]

  • 12. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 01; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 13. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
    Clayton A, Harris CL, Court J, Mason MD, Morgan BP.
    Eur J Immunol; 2003 Feb 01; 33(2):522-31. PubMed ID: 12645951
    [Abstract] [Full Text] [Related]

  • 14. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
    Ravindranath NM, Shuler C.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb 01; 103(2):231-9. PubMed ID: 17234541
    [Abstract] [Full Text] [Related]

  • 15. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR.
    Virology; 1994 Nov 15; 205(1):82-92. PubMed ID: 7526538
    [Abstract] [Full Text] [Related]

  • 16. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
    Mäenpää A, Junnikkala S, Hakulinen J, Timonen T, Meri S.
    Am J Pathol; 1996 Apr 15; 148(4):1139-52. PubMed ID: 8644856
    [Abstract] [Full Text] [Related]

  • 17. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
    Macor P, Mezzanzanica D, Cossetti C, Alberti P, Figini M, Canevari S, Tedesco F.
    Cancer Res; 2006 Apr 01; 66(7):3876-83. PubMed ID: 16585216
    [Abstract] [Full Text] [Related]

  • 18. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S, Frolkis I, Rashkovsky L, Ophir D, Fishelson Z.
    Am J Respir Cell Mol Biol; 1996 Dec 01; 15(6):731-7. PubMed ID: 8969267
    [Abstract] [Full Text] [Related]

  • 19. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
    Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT.
    J Gen Virol; 1997 Aug 01; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
    [Abstract] [Full Text] [Related]

  • 20. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC.
    J Clin Oncol; 2003 Apr 15; 21(8):1466-71. PubMed ID: 12697868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.